Cargando…

Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan

Background. To determine the maximum tolerable infusion rate of rituximab, and investigate the safety and feasibility of rapid infusion of rituximab for patients with CD20 positive B-cell lymphomas (CD20+NHL). Patients and Methods. 18 patients with CD20+NHL were registered. This study had six cohort...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yokoyama, Masahiro, Terui, Yasuhito, Takeuchi, Kengo, Nara, Eriko, Nakano, Kenji, Ueda, Kyoko, Nishimura, Noriko, Mishima, Yuko, Sakajiri, Sakura, Tsuyama, Naoko, Ozawa, Keiya, Hatake, Kiyohiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649348/ https://www.ncbi.nlm.nih.gov/pubmed/23691364 http://dx.doi.org/10.1155/2013/863909

Ejemplares similares

R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma
por: Mishima, Yuko, et al.
Publicado: (2012)

Intravascular Large B-cell Lymphoma of the Bilateral Ovaries and Uterus in an Asymptomatic Patient with a t(11;22)(q23;q11) Constitutional Translocation
por: Shigematsu, Yasuyuki, et al.
Publicado: (2016)

Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas
por: Tsuyama, Naoko, et al.
Publicado: (2017)

Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis)
por: Yokoyama, Masahiro, et al.
Publicado: (2021)

Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan
por: Yokoyama, Masahiro, et al.
Publicado: (2017)

Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2)
por: Yokoyama, Masahiro, et al.
Publicado: (2019)

Epstein-Barr virus gastric ulcer associated with ruxolitinib
por: Kusano, Yoshiharu, et al.
Publicado: (2016)

Klebsiella pneumoniae primary liver abscess associated with ruxolitinib
por: Kusano, Yoshiharu, et al.
Publicado: (2016)

The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations
por: Mishima, Y, et al.
Publicado: (2011)

High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy
por: Kusano, Y, et al.
Publicado: (2017)

Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study
por: Kinoshita, Tomohiro, et al.
Publicado: (2020)

TP53 and OSBPL10 alterations in diffuse large B-cell lymphoma: prognostic markers identified via exome analysis of cases with extreme prognosis
por: Dobashi, Akito, et al.
Publicado: (2018)

Radiation therapy for localized duodenal low-grade follicular lymphoma
por: Harada, Arisa, et al.
Publicado: (2016)

Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma
por: Kusano, Y, et al.
Publicado: (2017)

Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma
por: Kusano, Y, et al.
Publicado: (2017)

Phase I, multicenter, dose‐escalation study of avadomide in adult Japanese patients with advanced malignancies
por: Hatake, Kiyohiko, et al.
Publicado: (2020)

Role of Bone Marrow-Derived Monocytes/Macrophages in the Repair of Mucosal Damage Caused by Irradiation and/or Anticancer Drugs in Colitis Model
por: Takaba, Junji, et al.
Publicado: (2010)

Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
por: Ogura, Michinori, et al.
Publicado: (2013)

Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)

Lichenoid drug eruption associated with Bendamustine
por: Kusano, Y, et al.
Publicado: (2016)

SEVERE ADENOVIRUS PNEUMONIA IN RITUXIMAB INFUSIONS
por: BJORK, SARAH, et al.
Publicado: (2021)

Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?
por: Patel, Jolly, et al.
Publicado: (2013)

Allergic/infusion reactions reported with cetuximab and rituximab
por: Wolf, Ray A, et al.
Publicado: (2015)

Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study
por: Ohmachi, Ken, et al.
Publicado: (2018)

Acute Respiratory Distress Syndrome after Rituximab Infusion
por: Montero, Alberto J., et al.
Publicado: (2005)

Molecular Analysis of Oncogenes, ras Family Genes (N‐ras, K‐ras, H‐ras), myc Family Genes (c‐myc, N‐myc) and mdm2 in Natural Killer Cell Neoplasms
por: Sugimoto, Kei‐ji, et al.
Publicado: (2002)

Platelets Promote Tumor Growth and Metastasis via Direct Interaction between Aggrus/Podoplanin and CLEC-2
por: Takagi, Satoshi, et al.
Publicado: (2013)

Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study
por: Izutsu, Koji, et al.
Publicado: (2021)

Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies
por: Ogura, Michinori, et al.
Publicado: (2015)

Molecular Analysis of Tumor Suppressor Genes, Rb, p53,pl6INK4A, pl5INK4B and p14ARF in Natural Killer Cell Neoplasms
por: Sakajiri, Sakura, et al.
Publicado: (2001)

Acute Myocardial Infarction after First Dose of Rituximab Infusion
por: Gogia, Ajay, et al.
Publicado: (2014)

A Case of Coronary Vasospasm after Repeat Rituximab Infusion
por: Ke, Calvin, et al.
Publicado: (2015)

Ultrafast 30‐min infusion of a rituximab biosimilar (Truxima)
por: Pérez‐Persona, Ernesto, et al.
Publicado: (2023)

Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol
por: Riccio, Eleonora, et al.
Publicado: (2021)

Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar
por: Courville, Jocelyn, et al.
Publicado: (2021)

A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma
por: Ri, Masaki, et al.
Publicado: (2017)

Long-Term Response and Possible Cure of Patients With B-Cell Malignancies With Dose-Escalated Rituximab
por: Jacobs, Lauren M., et al.
Publicado: (2017)

Model-Informed Development of Sotalol Loading and Dose Escalation Employing an Intravenous Infusion
por: Somberg, John C., et al.
Publicado: (2020)

Brain Abscess following Rituximab Infusion in a Patient with Pemphigus Vulgaris
por: Al-Harbi, Talal M., et al.
Publicado: (2015)

Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma
por: Modelevsky, Lisa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4mlr9bp9ivgjqo28atg7m81s5r